1. How is the imaging grading of pneumoconiosis performed in 2009? According to the National Occupational Health Standards – Diagnostic Criteria for Pneumoconiosis promulgated in 2009, the specific diagnostic grading of pneumoconiosis is as follows: Subject of observation Those who have indeterminate pneumoconiosis-like imaging changes on X-ray chest radiographs of dust workers, the nature and extent of which require dynamic observation for a certain period of time. Pneumoconiosis stage I Small shadows of overall intensity grade 1, with a distribution of at least 2 lung areas. Pneumoconiosis II: Small shadows with an overall intensity of grade 2 over 4 lung areas, or small shadows with an overall intensity of grade 3 over 4 lung areas. Stage III pneumoconiosis has one of the following three manifestations: (1) the presence of large shadows with a length of not less than 20 mm and a short diameter of not less than 10 mm; (2) the presence of small shadows with an overall density of grade 3, with a distribution of more than 4 lung areas and an accumulation of small shadows; (3) the presence of small shadows with an overall density of grade 3, with a distribution of more than 4 lung areas and large shadows. 2. How is pneumoconiosis diagnosed? Pneumoconiosis can be diagnosed based on a reliable history of productive dust exposure, with chest imaging manifestations as the main basis, combined with on-site occupational hygiene, pneumoconiosis epidemiological survey data and health monitoring data, with reference to clinical manifestations and laboratory tests, and after excluding other similar diseases of the lungs. Percutaneous puncture of large shadows in the lungs for biopsy, as well as transbronchial lung biopsy are of value in supporting the diagnosis and differential diagnosis. When making a diagnosis of occupational pneumoconiosis, a diagnosis of occupational pneumoconiosis needs to be made against a pneumoconiosis diagnostic standard film with an overall density of small shadows of at least grade 1 and a distribution of at least 2 lung areas. 3. What are the complications of pneumoconiosis? Respiratory infections: bronchitis and pneumonia are the most common complications of pneumoconiosis. Spontaneous pneumothorax: lung tissue and dirty layer pleura rupture, air enters the pleura to form pneumothorax, which can be closed pneumothorax, tension pneumothorax or traffic pneumothorax. It is treated with oxygen therapy, closed chest drainage or surgical thoracoscopy. Pulmonary tuberculosis: More common, silica dust patients are more likely to have complications of pulmonary tuberculosis. Patients with pneumoconiosis tuberculosis often have shorter pneumoconiosis progression times and accelerated respiratory function deterioration. Lung cancer, mesothelioma: seen in asbestos workers and patients with asbestosis, silica dust is also a class I carcinogen. Chronic pulmonary heart disease: seen in patients with advanced pneumoconiosis, mostly due to chronic bronchitis causing airway narrowing, increased ventilation resistance, obstructive emphysema, and hypoxemia, resulting in pulmonary arterial pressure hypertension and involvement of the heart, with pulmonary heart disease. Respiratory failure: The progression of pneumoconiosis, combined lung infections, pneumothorax and other comorbidities in pneumoconiosis patients are the main causes of respiratory failure, requiring oxygen therapy and respiratory support. 4. What is the treatment strategy for pneumoconiosis? After pneumoconiosis is diagnosed, transfer out of dust work, symptomatic supportive treatment, and active comorbidities should be done as soon as possible according to national regulations. General treatment: pay attention to physical and mental health, reasonable nutrition, and rehabilitation exercises to enhance body resistance and improve quality of life. Active symptomatic treatment to reduce cough, coughing and shortness of breath symptoms. For patients with hypoxia, long course home oxygen therapy is required. Drug therapy: There are no effective drugs or therapies for pneumoconiosis so far. Currently, the more commonly used drugs are mainly composed of kirsilpine, piperaquine, powdered antibiotics, and organic aluminum preparations. There is a lack of randomized controlled studies with large samples to evaluate the safety and efficacy of drugs. Lung transplantation: an effective means of treating advanced silicosis, patients with indications should be included in the waiting list for transplantation as early as possible and undergo a standardized pre-transplant evaluation. China is limited to the immature development of lung transplantation technology, limited source of donor organs and high cost, which restrict the development of lung transplantation. Whole lung lavage: Whole lung lavage in patients with early stage pneumoconiosis can reduce the respiratory symptoms and decrease the load of dust deposition in the lungs. Current studies have found that whole lung lavage does not delay the decrease in lung function and has no improvement in chest imaging. There is a lack of evidence-based medical evidence to support whole-lung lavage techniques for the treatment of pneumoconiosis.